• Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference

    来源: Nasdaq GlobeNewswire / 09 3月 2022 09:12:44   America/Chicago

    Fort Lee, NJ, March 09, 2022 (GLOBE NEWSWIRE) --

    Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 34th Annual Roth Conference.

    Event34th Annual Roth Conference
    DateMarch 15, 2022
    Time2:30 PM Pacific Time (5:30 PM Eastern Time)
    FormatFireside Chat
    Linkhttps://wsw.com/webcast/roth43/nvct/1845484

    About Nuvectis Pharma

    Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling pre-clinical testing.

    For more information, please visit www.nuvectis.com.

    Nuvectis Pharma Contact:

    Ron Bentsur

    Chairman, Chief Executive Officer and President

    rbentsur@nuvectis.com

    Media Relations Contact:

    LifeSci Advisors on behalf of Nuvectis Pharma, Inc.

    Eric Goldstein

    Tel: 646-791-9729

    egoldstein@lifesciadvisors.com


    Primary Logo

分享